Kim Monkhorst

7.4k total citations · 2 hit papers
112 papers, 3.4k citations indexed

About

Kim Monkhorst is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Kim Monkhorst has authored 112 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pulmonary and Respiratory Medicine, 65 papers in Oncology and 34 papers in Cancer Research. Recurrent topics in Kim Monkhorst's work include Lung Cancer Treatments and Mutations (52 papers), Cancer Genomics and Diagnostics (34 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Kim Monkhorst is often cited by papers focused on Lung Cancer Treatments and Mutations (52 papers), Cancer Genomics and Diagnostics (34 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Kim Monkhorst collaborates with scholars based in Netherlands, United States and Switzerland. Kim Monkhorst's co-authors include Paul Baas, Vincent van der Noort, Ferry Lalezari, Jeltje F. de Vries, Joost Gribnau, Adrianus J. de Langen, Egbert F. Smit, Willemijn S.M.E. Theelen, Iris H. Jonkers and Joachim G.J.V. Aerts and has published in prestigious journals such as Cell, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Kim Monkhorst

103 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

2019 651 citations Willemijn S.M.E. Theelen, Ferry Lalezari et al. profile →
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

2021 195 citations Annegien Broeks, Alfred Zippelius et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kim Monkhorst Netherlands	28	1.8k	1.5k	986	665	455	112	3.4k
Fiona Thistlethwaite United Kingdom	21	1.9k 1.1×	631 0.4×	1.2k 1.2×	422 0.6×	567 1.2×	93	2.9k
Josep M. Piulats Spain	30	1.5k 0.8×	847 0.5×	1.1k 1.1×	448 0.7×	894 2.0×	162	3.2k
Owen N. Witte United States	28	932 0.5×	910 0.6×	1.2k 1.2×	463 0.7×	743 1.6×	46	3.1k
Minal Barve United States	25	1.8k 1.0×	659 0.4×	1.3k 1.3×	444 0.7×	654 1.4×	179	2.9k
Panagiota Economopoulou Greece	26	1.4k 0.8×	597 0.4×	891 0.9×	628 0.9×	392 0.9×	105	2.7k
Oscar Krijgsman Netherlands	27	1.4k 0.8×	426 0.3×	1.4k 1.4×	757 1.1×	493 1.1×	63	2.8k
Yasuhiro Koh Japan	32	2.0k 1.1×	1.4k 0.9×	1.1k 1.2×	801 1.2×	194 0.4×	131	3.3k
Kent W. Mouw United States	25	995 0.6×	860 0.6×	982 1.0×	617 0.9×	263 0.6×	117	2.6k
Leticia De Mattos‐Arruda Spain	26	1.3k 0.7×	735 0.5×	947 1.0×	1.4k 2.1×	209 0.5×	54	2.7k
Neeta Somaiah United States	30	1.4k 0.8×	1.7k 1.1×	793 0.8×	341 0.5×	383 0.8×	169	2.9k

Countries citing papers authored by Kim Monkhorst

Since Specialization

Citations

This map shows the geographic impact of Kim Monkhorst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Monkhorst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Monkhorst more than expected).

Fields of papers citing papers by Kim Monkhorst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Monkhorst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Monkhorst. The network helps show where Kim Monkhorst may publish in the future.

Co-authorship network of co-authors of Kim Monkhorst

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Monkhorst. A scholar is included among the top collaborators of Kim Monkhorst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Monkhorst. Kim Monkhorst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brandsma, Dieta, Els Verhoeven, Kim Monkhorst, et al.. (2025). Improving the diagnosis of leptomeningeal metastases by molecular profiling of cell-free DNA from cerebrospinal fluid. European Journal of Cancer. 229. 115783–115783. 1 indexed citations

Laan, P. van der, Winan J. van Houdt, Hester van Boven, et al.. (2025). The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma. ESMO Open. 10(6). 105287–105287. 1 indexed citations

Monkhorst, Kim, Gabe S. Sonke, Annegien Broeks, et al.. (2025). Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastases. The Breast. 85. 104674–104674.

Monkhorst, Kim, et al.. (2024). OA18.04 Pembrolizumab Plus Lenvatinib in Second-Line Pleural Mesothelioma Patients: A Single Arm Phase II Study (PEMMELA Cohort 2). Journal of Thoracic Oncology. 19(10). S50–S51.

Langen, Adrianus J. de, Kim Monkhorst, Houke M. Klomp, et al.. (2024). Survival difference between patients with single versus multiple metastatic lymph nodes and the role of histology in pathological stage II-N1 non-small cell lung cancer. Acta chirurgica Belgica. 124(5). 387–395. 1 indexed citations

Hummelink, Karlijn, Vincent van der Noort, Mirte Muller, et al.. (2024). Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. PLoS ONE. 19(7). e0293707–e0293707. 2 indexed citations

Schouten, Robert D., Vincent van der Noort, Ronald Damhuis, et al.. (2024). Optimising primary molecular profiling in non-small cell lung cancer. PLoS ONE. 19(7). e0290939–e0290939. 1 indexed citations

Boelens, Mirjam C., Merel J.A. Luitse, Annette Compter, et al.. (2024). Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study. Neuro-Oncology. 26(12). 2316–2327. 5 indexed citations

Dumoulin, Daphne W., Koen J. Hartemink, Monique Hochstenbag, et al.. (2024). The DETECTION project part 1: An international Delphi survey about diagnostics and treatment of anterior mediastinal cystic lesions. Lung Cancer. 199. 108055–108055.

10.

Wekken, Anthonie J. van der, Marthe S. Paats, Lizza Hendriks, et al.. (2023). A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer. Cancer. 130(5). 683–691. 4 indexed citations

11.

Langen, Adrianus J. de, Kim Monkhorst, Mirjam C. Boelens, et al.. (2023). Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC. JTO Clinical and Research Reports. 4(4). 100481–100481. 19 indexed citations

12.

Hummelink, Karlijn, Linda J.W. Bosch, Oscar Krijgsman, et al.. (2023). A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics. Clinical Cancer Research. 30(4). 814–823. 2 indexed citations

13.

Muller, Mirte, Myron G. Best, Vincent van der Noort, et al.. (2023). Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer. Tumor Biology. 46(s1). S327–S340. 1 indexed citations

14.

Hummelink, Karlijn, Vincent van der Noort, Mirte Muller, et al.. (2022). PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. Clinical Cancer Research. 28(22). 4893–4906. 26 indexed citations

15.

Woude, Lieke L. van der, Mark A.J. Gorris, Inge M. N. Wortel, et al.. (2022). Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. Journal for ImmunoTherapy of Cancer. 10(10). e005248–e005248. 28 indexed citations

16.

Koole, Simone N., Robert D. Schouten, Koen Degeling, et al.. (2022). Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance. Cancers. 14(7). 1783–1783. 5 indexed citations

17.

Schouten, Robert D., Linda J.W. Bosch, Nicole P. Barlo, et al.. (2021). Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology. 5(5). 1112–1121. 9 indexed citations

18.

Roepman, Paul, Ewart de Bruijn, Stef van Lieshout, et al.. (2021). Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics. Journal of Molecular Diagnostics. 23(7). 816–833. 39 indexed citations

19.

Muller, Mirte, Karlijn Hummelink, Daan P. Hurkmans, et al.. (2020). A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors. Clinical Cancer Research. 26(19). 5188–5197. 17 indexed citations

20.

Langen, Adrianus J. de, et al.. (2020). The force of HER2 – A druggable target in NSCLC?. Cancer Treatment Reviews. 86. 101996–101996. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact